Patrys Limited, the publicly-listed Australian drug development company, has acquired Reliis Pty Ltd for an undisclosed amount. This corporate acquisition sees Patrys, known for its work on antibody therapies for oncology and NETosis-driven inflammatory diseases, expand its strategic footprint. The transaction marks a definitive step in Patrys's growth, clearly establishing a purchase rather than a funding round.
Based in Melbourne, Patrys Limited (ASX: PAB) has been a significant player in biopharmaceutical development since its listing in 2007. The company focuses on two distinct technology platforms: IgM monoclonal antibodies and a suite of nuclear penetrating antibodies, including Deoxymab and 5C6, licensed from Yale University. Patrys aims to advance these lead candidates toward market commercialization, either through self-funding or co-development partnerships, targeting both cancer and inflammatory conditions.
This strategic acquisition of Reliis Pty Ltd is expected to bolster Patrys’s existing research and development efforts and accelerate the progression of its novel antibody pipeline. The synergy from integrating Reliis is anticipated to enhance Patrys's capacity to develop and commercialize its cutting-edge therapies. Patrys's existing track record includes out-licensing a clinical candidate for the Chinese market and conducting two clinical trials with a lead IgM platform candidate, demonstrating its commitment to bringing new treatments to patients.
The integration of Reliis is projected to strengthen the combined entity's capabilities, potentially accelerating the development of treatments for high-unmet-need diseases. With this acquisition, Patrys Limited positions itself for enhanced innovation and a more robust pipeline, aiming to deliver on its mission of fighting cancer and NETosis-driven inflammatory diseases with novel antibody approaches.